Overview

Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects

Status:
Recruiting
Trial end date:
2021-12-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Sodium Zirconium Cyclosilicate (SZC), as well as the appropriateness of the dosing mechanism, in Chinese end-stage renal disease (ESRD) patients on chronic haemodialysis.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca